GSK's Cabenuva maintains continuous viral suppression in 81% of patients in real-world study
GSK•A five-year U.S. real-world study of 6,955 adults who switched from daily oral HIV treatment found that 81% maintained continuous viral suppression on Cabenuva, GSK said.
1. Five-year study results
GSK-majority-owned ViiV Healthcare announced results from the OPERA study, which followed 6,955 adults who switched from daily oral treatment to Cabenuva. Most maintained viral suppression and remained on the treatment; confirmed treatment failure was uncommon. The results will be presented at IDWeek 2026 in Washington, D.C., October 21-24.
